A Better Risk Model for DLBCL Patients?

Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.

Source: CancerNetwork - December 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news